Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 1,865 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: First Treatment Period Clear all

Conditions: Bipolar Disorder
Interventions: Customized Adherence Enhancement (CAE), Enhanced Treatment as Usual (eTAU); Behavioral
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 3
States / cities: Cleveland, Ohio • Lorain, Ohio

Conditions: Non-Small-Cell Lung Carcinoma
Interventions: Cetuximab + platinum + gemcitabine, Platinum + Gemcitabine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 31
States / cities: Mobile, Alabama • Anchorage, Alaska • Bakersfield, California + 28 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Treprostinil Palmitil, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 2 more

Conditions: Breast Cancer, Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
Interventions: Tucatinib, Eribulin, Trastuzumab; Drug
Lead sponsor: Criterium, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Albuquerque, New Mexico + 3 more

Conditions: Gastric Cancer
Interventions: Cisplatin, Capecitabine, Telatinib; Drug
Lead sponsor: ACT Biotech, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 5
States / cities: San Francisco, California • Macon, Georgia • Philadelphia, Pennsylvania + 2 more

Conditions: Colorectal Neoplasms
Interventions: Modified Bolus 5-FU/LV with Irinotecan, FOLFIRI + bevacizumab, miFL + bevacizumab, Infusional 5-FU/LV with Irinotecan, Oral Capecitabine with Irinotecan; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 547 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 141
States / cities: Birmgingham, Alabama • Birmingham, Alabama • Birmngham, Alabama + 123 more

Conditions: Attention, Visual Perceptual Weakness, Social Behavior, Fluency Disorder, EEG With Periodic Abnormalities
Interventions: tDCS or Transcranial Direct Current Stimulation, Risperidone, Sham tDCS; Device · Drug · Other
Lead sponsor: Spanish Foundation for Neurometrics Development; Other
Eligibility: 6 Years to 11 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Pneumothorax
Interventions: Primary Surgery Group, Initial Non-operative management; Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 5 Years to 18 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: REM Sleep Behavior Disorder, Pre-motor Parkinson Disease, Symptomatic Parkinson Disease
Interventions: Carvedilol; Drug
Lead sponsor: Michele Tagliati, MD; Other
Eligibility: 50 Years to 85 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Rheumatoid Arthritis, Cardiovascular Disease
Interventions: Adalimumab, Placebo; Drug
Lead sponsor: Jonathan Graf; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Genital Herpes
Interventions: AIC316, Valacyclovir; Drug
Lead sponsor: AiCuris Anti-infective Cures AG; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Indianapolis, Indiana • Portland, Oregon • Houston, Texas + 1 more

Conditions: Medulloblastoma, Medulloblastoma, Childhood, Medulloblastoma Recurrent
Interventions: Liothyronine (L-T3), Bevacizumab, Irinotecan, Temozolomide (TMZ); Drug
Lead sponsor: Sabine Mueller, MD, PhD; Other
Eligibility: 1 Year to 25 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: San Francisco, California • Washington D.C., District of Columbia • Seattle, Washington

Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Interventions: Acute Intermittent Hypoxia, Sham Acute Intermittent Hypoxia; Other
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Obesity/Therapy
Interventions: Automated online weight loss program, Individual coaching, Group-based, videoconference-delivered weight loss; Behavioral
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years and older
Enrollment: 490 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Non-Hodgkin's Lymphoma
Interventions: Granulocyte-colony stimulating factor (G-CSF), Fixed Dose Plerixafor, Weight-Based Plerixafor; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Duarte, California • Aurora, Colorado

Conditions: Chronic Kidney Disease Requiring Chronic Dialysis
Interventions: Furosemide (loop diuretic) Tablets; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 5
States / cities: Carrboro, North Carolina • Pittsboro, North Carolina • Sanford, North Carolina + 1 more

Conditions: Anxiety, Stress
Interventions: Mindfulness Practice; Behavioral
Lead sponsor: Michigan State University; Other
Eligibility: 17 Years to 42 Years
Enrollment: 289 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: East Lansing, Michigan

Conditions: Restless Legs Syndrome
Interventions: Rotigotine; Drug
Lead sponsor: UCB BIOSCIENCES, Inc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 12
States / cities: Little Rock, Arkansas • Los Angeles, California • Orange, California + 9 more

Conditions: Treatment Resistant Depression
Interventions: Moderate Intensity Aerobic Exercise, Wait-list; Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Covid19
Interventions: Antiviral Agents, Monoclonal antibody; Drug
Lead sponsor: Pregistry; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Systemic Lupus Erythematosus (SLE)
Interventions: Acthar, Placebo, Steroid Drug; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 22
States / cities: Jonesboro, Arkansas • La Jolla, California • La Palma, California + 17 more

Conditions: Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma
Interventions: KW-0761; Biological
Lead sponsor: Kyowa Kirin Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Stanford, California

Conditions: Asthma
Interventions: Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI, Racemic Albuterol followed by levalbuterol HFA MDI; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 4
States / cities: Encinitas, California • Los Angeles, California • North Dartmouth, Massachusetts + 1 more

Conditions: Speech Sound Disorder
Interventions: Motor-based speech treatment; Behavioral
Lead sponsor: Syracuse University; Other
Eligibility: 7 Years to 11 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Syracuse, New York

Search by objective public record fields.

Effectiveness RCT of Customized Adherence Enhancement

Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric Cancer

Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.

Result of tDCS in ASD Children With Comorbidities Like PANDAS, Rare Genetic Diseases or Autoimmune Disorders

Primary Versus Delayed Surgical Therapy for Pediatric Spontaneous Pneumothorax

Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease (Protocol 53136)

Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease

Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes

Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease

Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS

Remote Approaches for Optimizing Weight Loss (Elevate Weight Loss Trial)

Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms

Pilot Study of Loop Diuretics Among Individuals Receiving Hemodialysis

Cluster-randomized Controlled Trial of Mindfulness-Based Cognitive Therapy Effects on Anxiety and Stress

Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome

Exercise in Treatment Resistant Depression (TRD): A Feasibility Study

COVID-19 International Drug Pregnancy Registry

Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease

Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001

A Safety and Tolerability Study of Levalbuterol HFA Metered Dose Inhaler in Subjects With Asthma

Treatment for /s/ Production Errors in Children With Speech Sound Errors